Literature DB >> 21254903

Association between depressive symptoms and metabolic syndrome is not explained by antidepressant medication: results from the PPP-Botnia Study.

Antti-Jussi Pyykkönen1, Katri Räikkönen, Tiinamaija Tuomi, Johan G Eriksson, Leif Groop, Bo Isomaa.   

Abstract

INTRODUCTION: To study whether the frequently reported association between depressive symptoms and the metabolic syndrome (MetS) and its individual components are secondary to the use of antidepressant medication and to established diabetes or cardiovascular diseases (CVD). PATIENTS AND METHODS: A population-based, random sample of 4,967 women and men aged 18-75 years. MetS was defined according to the new, harmonized criteria. Glucose tolerance was assessed by oral glucose tolerance test (OGTT). CVD, depressive symptoms, and use of antidepressant medication were self-reported.
RESULTS: The odds for having the MetS increased over 10%for each standard deviation increase in depressive symptoms. Users of antidepressant medication had more than 50% increased odds for having the MetS. Depressive symptoms were also associated with higher glucose response during the OGTT, higher serum triglyceride and lower HDL-cholesterol concentrations, and higher waist circumference, while use of antidepressant medication was associated with higher triglycerides, waist circumference, and systolic blood pressure. The associations of depressive symptoms were not secondary to use of antidepressant medication and were not explained by established diabetes or CVD. DISCUSSION: Depressive symptoms, the MetS, and the individual components of MetS are related. These associations are not driven by use of antidepressant medication, established diabetes, or CVD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21254903     DOI: 10.3109/07853890.2010.543921

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  11 in total

1.  Antidepressant use and glycemic control.

Authors:  Ramin Mojtabai
Journal:  Psychopharmacology (Berl)       Date:  2013-01-20       Impact factor: 4.530

2.  Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users.

Authors:  Nicole Vogelzangs; Aartjan T F Beekman; Arianne K B van Reedt Dortland; Robert A Schoevers; Erik J Giltay; Peter de Jonge; Brenda W J H Penninx
Journal:  Neuropsychopharmacology       Date:  2014-01-20       Impact factor: 7.853

Review 3.  Lipid effects of psychiatric medications.

Authors:  Junzo Watanabe; Yutaro Suzuki; Toshiyuki Someya
Journal:  Curr Atheroscler Rep       Date:  2013-01       Impact factor: 5.113

4.  Depressive symptoms, antidepressant medication use, and insulin resistance: the PPP-Botnia Study.

Authors:  Antti-Jussi Pyykkönen; Katri Räikkönen; Tiinamaija Tuomi; Johan G Eriksson; Leif Groop; Bo Isomaa
Journal:  Diabetes Care       Date:  2011-09-27       Impact factor: 19.112

5.  Subjective sleep complaints are associated with insulin resistance in individuals without diabetes: the PPP-Botnia Study.

Authors:  Antti-Jussi Pyykkönen; Bo Isomaa; Anu-Katriina Pesonen; Johan G Eriksson; Leif Groop; Tiinamaija Tuomi; Katri Räikkönen
Journal:  Diabetes Care       Date:  2012-07-26       Impact factor: 19.112

Review 6.  Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile.

Authors:  Brenda W J H Penninx; Yuri Milaneschi; Femke Lamers; Nicole Vogelzangs
Journal:  BMC Med       Date:  2013-05-15       Impact factor: 8.775

Review 7.  Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review.

Authors:  Katharine Barnard; Robert C Peveler; Richard I G Holt
Journal:  Diabetes Care       Date:  2013-10       Impact factor: 19.112

8.  Elevated depressive symptoms in metabolic syndrome in a general population of Japanese men: a cross-sectional study.

Authors:  Atsuko Sekita; Hisatomi Arima; Toshiharu Ninomiya; Tomoyuki Ohara; Yasufumi Doi; Yoichiro Hirakawa; Masayo Fukuhara; Jun Hata; Koji Yonemoto; Yukiko Ga; Takanari Kitazono; Shigenobu Kanba; Yutaka Kiyohara
Journal:  BMC Public Health       Date:  2013-09-18       Impact factor: 3.295

9.  Association between depressive symptoms, use of antidepressant medication and the metabolic syndrome: the Maine-Syracuse Study.

Authors:  Georgina E Crichton; Merrill F Elias; Michael A Robbins
Journal:  BMC Public Health       Date:  2016-06-10       Impact factor: 3.295

10.  BIDIRECTIONAL PROSPECTIVE ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH DEPRESSION, ANXIETY, AND ANTIDEPRESSANT USE.

Authors:  Sarah A Hiles; Dóra Révész; Femke Lamers; Erik Giltay; Brenda W J H Penninx
Journal:  Depress Anxiety       Date:  2016-04-27       Impact factor: 6.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.